GO
Loading...

Merck & Co Inc

More

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.

  • US STOCKS-Futures point to flat open after recent rally Thursday, 14 Aug 2014 | 8:54 AM ET

    *Cisco down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures pointed to a flat open on Thursday as investors found few reasons to buy following a sharp rally in the previous session and amid signs of weakness in Europe and ongoing uncertainty over Ukraine.

  • US STOCKS-Futures tick up ahead of jobless claims data Thursday, 14 Aug 2014 | 7:31 AM ET

    *Cisco shares down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures edged higher on Thursday, with investors reluctant to make big bets following a sharp rally in the previous session and amid signs of weak conditions in Europe. *Cisco Systems Inc fell 1.3 percent to $24.87 in premarket trading.

  • FDA approves new sleeping drug from Merck Wednesday, 13 Aug 2014 | 4:03 PM ET

    WASHINGTON— Merck& Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep. Doctors should warn patients taking the highest dose against next-day driving or activities that require full concentration, the FDA said.

  • 20 big profitable US companies paid $0 in taxes Wednesday, 13 Aug 2014 | 10:50 AM ET
    A Merck sign in front of the company's building in Summit, New Jersey.

    These 20 S&P 500 companies reported effective tax rates of 0% or lower in the second calendar quarter, despite reporting a profit during the period.

  • The R&D elite: America's most innovative companies Wednesday, 6 Aug 2014 | 6:00 AM ET

    The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.

  • The R&D Hall of Fame: Who makes the cut? Wednesday, 6 Aug 2014 | 6:00 AM ET

    Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.

  • NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • *Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • Stocks mixed; Fed tapers and GDP better than forecast Wednesday, 30 Jul 2014 | 4:07 PM ET

    Stocks turned mostly lower Wednesday as better-than-expected growth in the second quarter fostered talk of Fed rate hikes.

  • Wall Street ponders which matters more: Fed or GDP Tuesday, 29 Jul 2014 | 5:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    Wall Street on Wednesday will get two reads on the U.S. economy, one from the Commerce Department and the other from the Federal Reserve.

  • Stocks fall; Ukraine concerns overtake earnings cheer Tuesday, 29 Jul 2014 | 4:17 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    Stocks fell Tuesday as geopolitical issues came back into play, offsetting upbeat earnings.

  • Pharma CEOs: Tax system flaws help overseas rivals Tuesday, 29 Jul 2014 | 1:35 PM ET
    Ian Read, CEO, Pfizer,  leaves the House of Commons on May 14, 2014 in London.

    Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.

  • July 29- Pfizer Inc, which in May abandoned its $118 billion bid to buy AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 10:54 AM ET

    Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • Merck beats forecasts, as newer drugs offset generics Tuesday, 29 Jul 2014 | 10:39 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.

  • July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.